Official ESCRS | European Society of Cataract & Refractive Surgeons
Maastricht 2017 Meeting Highlights Registration Programme Overview Exhibition Virtual Exhibition Hotels Satellite Meetings Visa Letter Application Star Alliance Travel Discount
title

10 - 12 February 2017, MECC Maastricht,The Netherlands.

This Meeting has been awarded 15 CME credits.

Posters

Search Abstracts by author or title
(results will display both Free Papers & Poster)

The efficacy of Alahmady Ring implantation in management of neovascular glaucoma

Poster Details


First Author: A. Hasan EGYPT

Co Author(s):                     

Abstract Details

Purpose:

To evaluate the efficacy and safety of Alahmady ring implantation in the management of neovasular glaucoma.

Setting:

Sohag Faculty of Medicine Egypt

Methods:

A retrospective analysis of 15 eyes of 15 patients with intractable neovasular glaucoma with intraocular pressure (IOP) ≥28 mm Hg not responding to medical treatment. All patients underwent implantation of Alahmady ring which designed from fenestrated silicon tube used in lacrimal surgeries and implanted subscleral after passage through the anterior chamber. Patients were followed up for at least 24 months .Success in this study was defined as intraocular pressure (IOP) ≥8 mm Hg and ≤21 mm Hg, with not more than one glaucoma drug , and improvement of patient symptoms and improvement of signs of congestion.

Results:

15 eyes of 15 patients 9 males(60%) and 6 females(40%) involved in this study The median IOP before surgery was 33.82 mmHg (SD: 6.98), and it was 14.05 mmHg (SD: 7.57) postoperatively. The range of follow-up was 24 months to 36 months. Success of Ahmady drainage device was defined as an IOP less than 21 mmHg with or without medication on the last follow-up visit, The medication with only one anti glaucoma drug and without severe complications or further glaucoma surgery.

Conclusions:

Ahmady Ring implantation is a good surgerical option for neovascular glaucoma however longer follow up period is recommended.

Financial Disclosure:

None

Back to Poster listing